Literature DB >> 11893431

Pulmonary prostacyclin is associated with less severe respiratory distress in preterm infants.

Patrik Lassus1, Lasse Viinikka, Olavi Ylikorkala, Maija Pohjavuori, Sture Andersson.   

Abstract

BACKGROUND: Prostacyclin (PGI(2)) and thromboxane A(2) (TxA(2)) may take part in lung pathology; high concentrations of PGI(2) may protect newborn rabbits against hyperoxic lung injury, and TxA(2) may participate in the development of bronchopulmonary dysplasia (BPD). AIMS: To examine in small preterm infants, the relationship between pulmonary PGI(2) and TxA(2) and respiratory distress during the early postnatal period.
METHODS: The stable metabolite of prostacyclin, 6-keto-prostaglandinF(1 alpha), and that of thromboxane A(2), thromboxane B(2), were quantified by radioimmunoassays in 284 samples of tracheal aspirates from 48 infants (GA: 27.4+/-2.1 week, BW 959+/-334 g) during the first 12 postnatal days.
RESULTS: Mean concentration of 6-keto-prostaglandinF(1 alpha) was 414+/-31 pg/ml (mean+/-S.E.M.), and of thromboxane B(2) was 418+/-37 pg/ml. Correlations existed between 6-keto-prostaglandinF(1 alpha) and gestational age, birth weight, and the initial arterial-alveolar oxygenation ratio. Negative correlations existed between 6-keto-prostaglandinF(1 alpha) and both mean inspiratory oxygen and duration of mechanical ventilation. Indomethacin treatment was associated with lower pulmonary 6-keto-prostaglandinF(1 alpha), but not with lower TxB(2). Thromboxane B(2) correlated positively with gestational age, birth weight, and initial arterial-alveolar oxygenation ratio, and inversely with duration of mechanical ventilation.
CONCLUSIONS: In preterm infants, higher pulmonary 6-keto-prostaglandinF(1 alpha) was associated with less severe respiratory distress and with maturity, whereas thromboxane B(2) was associated more strongly with maturity than with respiratory distress.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893431     DOI: 10.1016/s0378-3782(01)00244-4

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  3 in total

1.  Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants.

Authors:  Erik A Jensen; Kevin C Dysart; Marie G Gantz; Benjamin Carper; Rosemary D Higgins; Martin Keszler; Matthew M Laughon; Brenda B Poindexter; Barbara J Stoll; Michele C Walsh; Barbara Schmidt
Journal:  J Pediatr       Date:  2017-02-28       Impact factor: 4.406

2.  Iloprost improves endothelial barrier function in lipopolysaccharide-induced lung injury.

Authors:  Anna A Birukova; Tinghuai Wu; Yufeng Tian; Angelo Meliton; Nicolene Sarich; Xinyong Tian; Alan Leff; Konstantin G Birukov
Journal:  Eur Respir J       Date:  2012-07-12       Impact factor: 16.671

Review 3.  Biomarkers in Pediatric ARDS: Future Directions.

Authors:  Benjamin E Orwoll; Anil Sapru
Journal:  Front Pediatr       Date:  2016-06-01       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.